Browsing by Author Kilburn, L

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2015Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trialsCoates, Alan; Aihara, T; Bliss, J; Boccardo, F; Bradley, R; Coombes, R; Cuzick, J; Dowsett, Mitch (Prof); Dubsky, P; et al, Various; Forbes, John F.; Gnant, Michael; Ingle, J.; Kaufmann, Michael; Kilburn, L; School of Public Health: Public HealthAromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials, The Lancet, vol.386, 10001, 2015,pp 1341-1352
2017Long-term follow-up of The Intergroup Exemestane StudyCoates, Alan; Alvarez, Isabel; Andersen, Jorn; Bertelli, Gianfilippo; Bliss, Judith; Coleman, Robert; Coombes, R. Charles; Del Mastro, Lucia; Dodwell, David; Fallowfield, L. J.; Holmberg, Stig; Jassem, Jacek; Jones, Stephen E; Kilburn, L; L√łnning, Per; Morden, James; Nicholas, Hanna; Ortmann, Olaf; Paridaens, Robert; Snowdon, Claire; van de Velde, C; NH&MRC Clinical Trials CentreLong-term follow-up of The Intergroup Exemestane Study, Journal of Clinical Oncology, vol.35, 22, 2017,pp 2507-2514
2007Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialCoates, Alan; Coleman, R; Coombes, C; Delozier, E; et, al; Jassem, J; Jones, S; Kilburn, L; Paridaens, R; Snowdon, C; van de Velde, C; School of Public Health: Public HealthSurvival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial, The Lancet, vol.369,(9561),2007,pp 559-570